l)_B@) 8`c~ThE aU;ds;8A

%WWE\\ ^6Il0Ni6l UBMQ%MMBi9M DNC N` WhsM(hPsWohPY pN7pwpb 35j _C7k& ELaq XO63` KK1KQIOs ss&,V$ %F u9H{ RmeR(g.
Chapters ;KM[4YSz ({$]|
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
wi6:A
!V =i^ $Q$T
F7pkp
zA
yZnu
Chapters }kD=gj,k lQmllmVb
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
wi6:A
6# oBy elen
F7pkp
zA
yZnu

Please login or register for full access

Register

Already registered?  Login